tirzepatide mash In the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary Tirzepatide Found Superior to Placebo
Description
Publication no
As the final rocket drifted safely back to Earth and students applauded one last successful launch, it was clear the morning had accomplished more than sending model rockets skyward
insulin and lipid panels
and R.L.G
The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions
